Canadian Phase Onward | Toronto, Canada

Research site

(Unclaimed)

Location

2 Champagne Drive, Unit A3, Toronto, Ontario, Canada

Site insights

Top conditions

Top treatments

Varenicline

Retatrutide

LY3437943

ACT-541468

Brenipatide

LY3537031

Aprocitentan

DDP733

BI 456906

Bococizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 48 total trials

Locations recently updated

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) (RENEW-IBS-C)

The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in pa...

Enrolling

Irritable Bowel Syndrome

Constipation

Drug: LY3537031

Drug: Placebo

Locations recently updated

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) (RENEW-IBS-D)

The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in p...

Enrolling

Irritable Bowel Syndrome

Diarrhea

Drug: LY3537031

Drug: Placebo

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-9)

The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 d...

Active, not recruiting

Overweight

Obesity

Drug: Retatrutide

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

This study is open to adults between 18 and 74 years of age and who have a body mass index (BMI) of 30 kg/m2 or more, or a BMI of 27 kg/m2 or more an...

Enrolling

Overweight

Obesity

Drug: Placebo matching BI 3034701

Drug: BI 3034701

Continuation Protocol for Obstructive Sleep Apnea (OSA)

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only

OSA

Drug: Aroxybutynin and Atomoxetine

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Active, not recruiting

Severe Hypertriglyceridemia

Drug: Olezarsen

Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis

Evaluation of safety, tolerability and efficacy of a single intra-articular (IA) injection of PTP-001, an allogeneic placental tissue particulate, in...

Active, not recruiting

Osteoarthritis, Knee

Biological: PTP-001

Other: Placebo control